Xenon Pharmaceuticals Inc. (XENE) Cash Flow Statement

The OCF/NI ratio has been above 1 in most quarters, reaching 1.66 in 2026Q2, which suggests that non-cash charges like stock-based compensation are not the primary driver of cash burn; instead, working capital and other cash items are amplifying the outflow. This divergence implies that the company's cash runway is being consumed faster than net losses suggest, a critical signal for a pre-revenue biotech.

The FCF trajectory is sharply negative and accelerating, with quarterly burn more than tripling over ten quarters. This aligns with the income statement's 124% increase in R&D expenses, indicating that the company is intentionally scaling clinical programs. However, without revenue, this burn rate is unsustainable without external financing, and investors should monitor the pace of cash consumption relative to pipeline milestones.

The negligible capex suggests that Xenon's business model is asset-light, relying on outsourced manufacturing and research rather than heavy infrastructure. This is typical for a clinical-stage biotech, but it also means that the cash burn is almost entirely operational, driven by R&D and SG&A. The low capital intensity implies that future growth will not require significant capex, but the company's survival hinges on successful drug development.

The working capital adjustments are minor relative to the overall cash outflow, suggesting that the company is not experiencing significant inventory or receivable issues, which is consistent with a pre-revenue stage. However, the negative changes in some quarters (e.g., -$12.2M in 2025Q1) may reflect timing of payments or prepaid expenses, but they do not materially alter the burn trajectory. Investors should focus on the core operating cash flow rather than these small fluctuations.

The absence of capital returns is expected for a clinical-stage biotech, but it underscores that shareholder value is entirely dependent on pipeline success. The company is not returning cash to shareholders, and with no acquisitions, the cash is being funneled into internal development. This deployment strategy is coherent with the income statement's escalating R&D, but it also means that any financing need will likely come from equity or debt, diluting existing shareholders.

The cumulative OCF is actually less negative than net income (by about $57.7M), which is unusual; this suggests that non-cash charges like SBC and D&A are adding back, but working capital changes have been a net use of cash. However, the gap is not large, implying that the accounting losses are a reasonable proxy for cash consumption. The key takeaway is that the company is burning cash at a rate that will require substantial financing, and the cumulative gap does not indicate any hidden cash generation.